reports
- Emma Ulker
Review underway after Atopic Dermatitis miss
Realm Therapeutics plc (RLM), a clinical stage bio-pharmaceutical company focused on developing novel therapeutics in immune-related diseases based on its proprietary hypochlorous acid (HOCl) technology, has reported preliminary top-line data from its Phase II trial of PR022 in Atopic Dermatitis, in tandem with H1’18 financial results. RLM’s randomised, double-blind, placebo controlled, Phase II clinical trial, PR022 showed no difference from vehicle in the primary endpoint of percentage cha...
- Emma Ulker
On track for Atopic Dermatitis readout in Q3
Realm Therapeutics (RLM) is developing a pipeline of novel topical treatments for highly prevalent dermatology indications using its proprietary stabilised hypochlorous acid (HOCl) technology. RLM is investigating the potential already seen in its preclinical studies with topical HOCl formulations to date. They suggest immunomodulatory activity alongside well-documented safety evidence: an encouraging base from which to potentially deliver efficacious and safer alternatives to first line therapi...
- Emma Ulker
Atopic Dermatitis the focus in 2018
Realm Therapeutics (RLM) is developing a pipeline of novel topical treatments principally to treat highly prevalent dermatology indications using its proprietary hypochlorous acid (HOCl) technology, which has shown immunomodulatory properties coupled with a potentially favourable safety profile. FY’17 highlights included entry of lead program PR022 a topical gel to treat Atopic Dermatitis into FDA Phase II study due to provide headline data in Q3’18. RLM is on track to file an Investigatio...
- Emma Ulker
Focus on the dermatology pipeline
Realm Therapeutics, based in Malvern PA, is an emerging specialty bio-pharmaceutical company developing therapeutic products to treat immune related disorders in adults and children, using its proprietary HOCl - hypochlorous acid based technology. RLM’s lead candidate is a topical gel, PR022 for Atopic Dermatitis (AD). Realm reports that top line results from its Phase II study of PR013 in Allergic Conjunctivitis (AC) failed to show efficacy and that consequently it has decided to cease furth...
- Emma Ulker
Funded pipeline progressing at speed
Realm Therapeutics (RLM), based in Malvern PA, is an emerging specialty bio-pharmaceutical company developing therapeutic products to treat immune related disorders in adults and children, using its proprietary Hypochlorous acid-based technology. RLM’s lead candidates include the topical gel, PR022 for Atopic Dermatitis (AD), and PR013, a topical solution to treat Allergic Conjunctivitis (AC). RLM has today reported that it is making excellent progress advancing its proprietary therapeutic pi...
- Emma Ulker
Realm Therapeutics plc: Moving to the timelines
Realm Therapeutics (RLM) reports alongside FY16 financial results that its clinical pipeline is advancing to plan. RLM also confirms that both of its lead candidates - PR022, a novel high concentration formulation of hypochlorous acid (HOCl) to treat Atopic Dermatitis (AD) and PR013 to treat Allergic Conjunctivitis (AC) - will move into Phase II studies in 2017. Consequently, top line data readouts for both candidates is anticipated during H118. The novel topical treatments aim to provide effic...
A New Realm of Opportunity
​Realm Therapeutics (RLM) is an emerging specialty bio-pharmaceutical company developing therapeutic products to treat immune related disorders in adults and children, using its proprietary hypochlorous acid-based technology. RLM (formerly PuriCore plc) is now a focused entity, having divested its non-strategic supermarket retail business for $13.5m to Chemstar Corp in October 2016.RLM is preparing to take its pipeline of novel pharmaceutical therapies, which hinges on patented high concentrat...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.